Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term open-label extension of migalastat monotherapy in Fabry disease
2014-002701-38Phase 3Completed
- Sponsor
- Amicus Therapeutics
- Start
- Nov 2014
- Modality
- Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of migalastat in Fabry disease (FD), sponsored by Amicus Therapeutics. Primary endpoint: Adverse events, possible suicidality related adverse events, and serious adverse events. Started Nov 2014; status: completed.
02
Drugs
migalastat
03
Conditions
Fabry disease (FD)
Beyond the preview
Go deeper on 2014-002701-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-002701-38.